Back to Blog
Antibody production cells7/25/2023 ![]() * A phage is a virus that infects specific bacteria. In addition, utilizing the advantages of the phage display method in finding rare antibodies, we are developing methods for obtaining antibodies against G protein-coupled receptors (GPCRs) or glycosylated epitope - which, despite being useful drug discovery targets, are very difficult to produce antibodies for - and methods for efficiently selecting antibodies from vast antibody libraries by Next Generation Sequencing (NGS) and data science. MBL owns a large number of human antibody libraries including 1 to 10 billion different antibodies, and we have succeeded in developing tumor-specific (suppressant) antibodies and virus neutralizing antibodies. ![]() The technology is also useful for producing antibodies against highly lethal toxins and viruses because it is possible to construct antibody libraries without the laboratory work of animal immunization with antigens. With this technology, vast antibody libraries including a very broad variety of antibodies can be constructed, so extremely rare and high affinity antibodies can be obtained quickly and efficiently. The phage display method is a procedure to obtain antibodies that bind to target molecules (antigens) by presenting antibodies (e.g., Fab scFv) to fibrous phages of E. Production of Human Monoclonal Antibodies by Phage Display Method * MBL employs the phage display method and fusion partner technology (using the fusion partner cell line, SPYMEG) to efficiently obtain human monoclonal antibodies as the “seeds” of antibody drugs by making the best use of the advantages of each of these technologies. There are different methods for producing fully human antibodies: phage display technology, immunization of humanized transgenic mice which are genetically engineered to produce fully human antibodies, sequencing analysis of antibody genes from human antibody-producing cells, and a technology to fuse antibody-producing cells and fusion partners. Since human antibodies are not recognized as foreign substances in the human body, they are considered to be highly effective and safe treatments. 22:1539-1545 (2004) (PubMed: 15568019) Human Monoclonal Antibody-Producing TechnologyĬurrently available antibody drugs include humanized antibodies and fully human antibodies generated from human genes. Also this MBL technology can provide antibodies with extremely high binding affinity.ġ) Suematsu S. In monoclonal antibody-production using this technology, the number of monoclonal antibodies obtained is more than 10 times larger than what can be done by conventional methods. When artificial lymph nodes formed in immunized mice are transplanted into immunodeficient mice, they are capable of producing an antibody titer for target antigens that is 10 to 100 times higher than that in normal mice. Normal lymph nodes contain immune cells that respond to various antigens, whereas artificial lymph nodes have a distinct feature in that they consist of only targeting antigen-specific immune cells. The technology was developed for the preparation of artificial lymph nodes in the kidney of mice. MBL’s artificial lymph node technology is a highly efficient antibody-production technology based on the method created by Professor Takeshi Watanabe at the National Research and Development Institute, RIKEN, and his associates. ![]() Recombinant Protein Production Technology.SPYMEG, Fusion Partner Cell Line for fully Human Monoclonal Antibodies.Production of Human Monoclonal Antibodies by Phage Display Method.Human Monoclonal Antibody-Producing Technology.Additionally, understanding genomic and metabolic differences between the two cell hosts from an 'omics perspective has created a reference for media composition and antibody quality improvements. Even though the major components of the cell culture media are common for both CHO and NS0 cells, specific growth media have been modified based on individual cellular requirements, such as cholesterol for NS0 cells. Several different expression platforms are available: CHO-GS (glutamine synthetase), CHO-DHFR (dihydrofolate reductase), NS0, and GS-NS0, which have been characterized with respect to cell line and process development. By 2017, nearly one-quarter of all approved mAbs in the market were produced using the NS0 host cell line, and around two-thirds were produced in CHO cells. Two cell hosts are predominantly utilized to produce these mAbs: Chinese hamster ovary (CHO) cells and murine myeloma cells (NS0). ![]() These biotherapeutics have the potential to generate a global annual revenue of more than US$150 billion. The commercial production of monoclonal antibodies (mAbs) has revolutionized the treatment of many diseases, including cancer, multiple sclerosis, and rheumatoid arthritis.
0 Comments
Read More
Leave a Reply. |